A run of cancer and gastrointestinal research from NYU Langone Health this past week underscored the city’s role as a hub for clinical innovation, with new findings on tumor survival mechanisms, colonoscopy effectiveness, and personalized pancreatic cancer vaccines drawing attention across the major medical meetings of the spring season. Several of the studies were spotlighted at Digestive Disease Week 2026, the field’s largest annual gathering, while others appeared in peer-reviewed journals and trade press.
A New Window Into Why Some Tumors Resist Treatment
Researchers at NYU Langone Health, working through the Institute for Systems Genetics and Perlmutter Cancer Center, published findings in Molecular Cell explaining how cancer cells with abnormal chromosome numbers survive treatments that should kill them.
The team found that these aneuploid cells carry 50 to 60 percent less PARP1 protein, a deficit that prevents cell death when the cells face oxidative DNA damage. According to NYU Langone’s newsroom, the researchers identified that lysosomal stress activates a factor that suppresses the PARP1 gene, a mechanism that had not previously been mapped.
Senior author Teresa Davoli, PhD, associate professor in the Department of Biochemistry and Molecular Pharmacology at NYU Grossman School of Medicine, noted the findings open new therapeutic possibilities. The work suggests potential drug targets for cancers driven by chromosomal instability, a category that includes a substantial share of advanced solid tumors. Medical Xpress also reported on the study.
Colonoscopy at 13 Years: A Cleaner Picture
At Digestive Disease Week 2026, NYU Langone gastroenterologist Aasma Shaukat, MD, MPH, weighed in on one of the most-watched data sets of the year: the 13-year update from the Nordic-European Initiative on Colorectal Cancer (NordICC) trial. The trial, which followed more than 84,000 people across Norway, Poland, and Sweden, found that a single colonoscopy reduced colorectal cancer incidence over 13 years but did not significantly reduce mortality.
Shaukat, the Robert M. and Mary H. Glickman Professor of Medicine at NYU Grossman School of Medicine and director of Outcomes Research for Gastroenterology and Hepatology, provided commentary on the findings for Medscape and the European Medical Journal. She told EMJ the results compel a recalibration of what colonoscopy can achieve at a population level. In her Medscape commentary, Shaukat called the lack of mortality reduction in women “quite concerning” and suggested the unexpectedly low mortality in the no-screening group may reflect broader improvements in cancer care.
The DDW conversation extended beyond colonoscopy. Shaukat highlighted research on GLP-1 medications for metabolic dysfunction-associated steatotic liver disease (MASLD), the increasingly common condition formerly known as nonalcoholic fatty liver disease. She also pointed to the DUET-CD study on a co-antibody therapy for Crohn’s disease, presented at DDW by Bruce Sands, MD, of Mount Sinai, which showed superior efficacy in treatment-refractory patients without additional safety concerns.
A Brooklyn Trial Reframes Screening Outreach
A separate NYU Langone clinical trial, conducted at eight federally qualified health centers in Brooklyn with 1,275 adults, tested whether automated text messages could outperform standard nurse-led phone calls in driving colorectal cancer screening. The result: nearly 59 percent of patients who received text reminders completed their at-home fecal immunochemical test, compared with about 50 percent in the phone call group.
The findings, reported by Black Doctor, point to a low-cost, scalable intervention for low-income and historically underserved communities, a category that includes large portions of the city’s outer-borough patient population.
Personalized mRNA Vaccines for Pancreatic Cancer
Paul E. Oberstein, MD, an oncologist at NYU Langone, service chief of the Gastrointestinal Medical Oncology Program, and assistant director of the Pancreatic Cancer Center at Perlmutter Cancer Center, discussed personalized mRNA vaccines for pancreatic cancer in an interview with CURE Magazine published May 10.
The approach uses a patient’s own tumor to design a vaccine that trains the immune system to attack cancer cells. Oberstein highlighted a study in which roughly half of 16 patients showed a robust immune response, and strong responders saw a six-year survival rate near 90 percent, well above the 20 to 30 percent typically seen at five years.
A related NYU Langone-affiliated study published in The New England Journal of Medicine, reported by Becker’s Hospital Review, found that the drug daraxonrasib extended progression-free survival for stage 4 pancreatic cancer patients by a median of 8.5 months, with median overall survival of 13.1 months and a 35 percent response rate. The trial involved 15 cancer centers, including NYU Langone, and the FDA has granted expanded access. A phase 3 trial is now underway.
Safety Ratings and Institutional Recognition
NYU Langone’s clinical track record received outside validation this week. The Leapfrog Group awarded its spring 2026 “A” hospital safety grades to 40 New York hospitals, including NYU Langone Hospital—Long Island, NYU Langone Hospital—Brooklyn, and NYU Langone’s Tisch Hospital and Helen L. and Martin S. Kimmel Pavilion, according to The Times Herald. The three facilities were also recognized with a “Straight A” designation for sustained patient safety performance. Other NYC-area hospitals receiving “A” grades included facilities from Northwell Health, NewYork-Presbyterian, and Mount Sinai.
For New York City patients, the practical implications stretch across both routine and complex care. The NordICC commentary may shape how primary care physicians and gastroenterologists across the five boroughs counsel patients about screening intervals. The Brooklyn text-message trial offers a template for how community health centers and city-run clinics can lift screening rates without adding staff or budget. The pancreatic cancer findings expand the menu of options available at Perlmutter Cancer Center, one of the city’s main referral destinations for advanced GI malignancies.
The week also reflects something broader about the geography of medical research. With Memorial Sloan Kettering, Mount Sinai, NewYork-Presbyterian, and NYU Langone all running large translational programs within roughly a 10-mile radius, New York remains one of the small handful of metro areas where patients can access experimental therapies, randomized trials, and post-trial expanded-access programs without leaving the region. The findings surfacing this month — from chromosomal instability research to mRNA vaccine response data — are the kinds of pipeline updates that determine which treatment options reach city patients first.
Disclaimer: This article is for general informational purposes only and does not constitute medical advice. The findings and expert commentary referenced are drawn from publicly available sources and should not be interpreted as recommendations for specific medical decisions. Consult a qualified healthcare provider for guidance on screening, treatment, or any health concern. NYWire is not affiliated with the institutions or researchers mentioned, and references do not constitute endorsement. Clinical trial data and survival statistics reflect findings as reported and may evolve with further research.
